Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Exercise Metabolism in Nonobese Patients with Type 2 Diabetes Following the Acute Restoration of Normoglycaemia.

Gaffney CJ, Mansell P, Stephens FB, Macdonald IA, Tsintzas K.

J Diabetes Res. 2017;2017:8248725. doi: 10.1155/2017/8248725. Epub 2017 May 29.

2.
3.

TREATMENT OF TYPE 2 DIABETES WITH BIPHASIC INSULIN ANALOGUES.

Rizvi AA.

Eur Med J Diabetes. 2016;4(1):74-83. Epub 2016 Oct 27.

4.

Efficacy and safety of biphasic insulin aspart and biphasic insulin lispro mix in patients with type 2 diabetes: A review of the literature.

Kumar A.

Indian J Endocrinol Metab. 2016 May-Jun;20(3):288-99. doi: 10.4103/2230-8210.179993. Review.

5.

Efficacy and safety of patient-directed titration of once-daily pre-dinner premixed biphasic insulin aspart 70/30 injection in Japanese type 2 diabetic patients with oral antidiabetic drug failure: STEP-AKITA study.

Narita T, Goto T, Suganuma Y, Hosoba M, Morii T, Sato T, Fujita H, Miura T, Shimotomai T, Yamada Y, Kakei M.

J Diabetes Investig. 2011 Jan 24;2(1):63-70. doi: 10.1111/j.2040-1124.2010.00062.x.

6.

Safety and effectiveness of biphasic insulin aspart 30 in different age-groups: a1chieve sub-analysis.

Khamseh ME, Haddad J, Yang W, Zilov A, Bech OM, Hasan MI.

Diabetes Ther. 2013 Dec;4(2):347-61. doi: 10.1007/s13300-013-0033-z. Epub 2013 Jul 17.

7.

Safety and Effectiveness of Switching from a Basal-only to Biphasic Insulin Aspart 30 Insulin Regimen.

Haddad J, Khoshniatnikoo M, Benabbas Y, Guler S, Prusty V, Soewondo P.

Diabetes Ther. 2013 Dec;4(2):309-19. doi: 10.1007/s13300-013-0032-0. Epub 2013 Jul 12.

8.

Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings.

Liebl A, Prusty V, Valensi P, Kawamori R, Christiansen JS, Palmer AJ, Balschmidt P, Ligthelm R, Mohan V.

Drugs. 2012 Jul 30;72(11):1495-520. doi: 10.2165/11635490-000000000-00000. Review.

9.

Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations.

Uy J, Fogelfeld L, Guerra Y.

Diabetes Metab Syndr Obes. 2012;5:1-10. doi: 10.2147/DMSO.S15404. Epub 2012 Jan 10.

10.

The impact of initiating biphasic human insulin 30 therapy in type 2 diabetes patients after failure of oral antidiabetes drugs.

Gu Y, Hou X, Zhang L, Pan J, Cai Q, Bao Y, Jia W.

Diabetes Technol Ther. 2012 Mar;14(3):244-50. doi: 10.1089/dia.2011.0168. Epub 2011 Nov 2.

11.
12.

Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes.

Yamanouchi T.

Vasc Health Risk Manag. 2010 Apr 15;6:189-97. Review.

13.

Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.

Lund SS, Tarnow L, Frandsen M, Nielsen BB, Hansen BV, Pedersen O, Parving HH, Vaag AA.

BMJ. 2009 Nov 9;339:b4324. doi: 10.1136/bmj.b4324.

14.

Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study.

Shah S, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shestakova M, Wenying Y, Valensi P; IMPROVE Study Group Expert Panel.

Int J Clin Pract. 2009 Apr;63(4):574-82. doi: 10.1111/j.1742-1241.2009.02012.x. Epub 2009 Feb 5.

15.

Initiating or switching to biphasic insulin aspart 30/70 therapy in subjects with type 2 diabetes mellitus. An observational study.

Breum L, Almdal T, Eiken P, Lund P, Christiansen E; Danish BIAsp Study Group.

Rev Diabet Stud. 2008 Fall;5(3):154-62. doi: 10.1900/RDS.2008.5.154. Epub 2008 Nov 10.

16.

Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes.

Qayyum R, Bolen S, Maruthur N, Feldman L, Wilson LM, Marinopoulos SS, Ranasinghe P, Amer M, Bass EB.

Ann Intern Med. 2008 Oct 21;149(8):549-59. Epub 2008 Sep 15. Review.

17.

Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes.

Raja-Khan N, Warehime SS, Gabbay RA.

Vasc Health Risk Manag. 2007;3(6):919-35. Review.

Supplemental Content

Support Center